Changing Electrolyte and Acido-Basic Profile in HIV-Infected Patients in the HAART Era
- 1 June 2006
- journal article
- research article
- Published by S. Karger AG in Nephron Physiology
- Vol. 103 (3) , p131-p138
- https://doi.org/10.1159/000092247
Abstract
Background: HIV-infected patients may develop a variety of underreported metabolic abnormalities that may be classified into HIVAN, specific HIV abnormalities, coincidental renal disorders and anti-retroviral-treatment-induced side effects. Methods: Our descriptive cross-sectional study evaluates the prevalence of electrolyte and acid base disorders in HIV patients in the HAART era in a tertiary care teaching hospital. All consecutive HIV-infected patients (n = 1,232) presenting at our Department of Infectious Disease over 3 months were included. Measurements: All available biochemical data obtained at admission or on the day of the visit were analyzed. We identified risk factors for electrolyte and acid base disorders with univariate regression analysis and multivariate stepwise regression analysis. Variables tested for significance included age, sex, absolute CD4 and CD8 counts, hepatitis B and C antibodies, and use and type of anti-retroviral medication. Results: Most frequent and clinically relevant abnormalities were hyperuricemia in 41.3%, hypophosphatemia in 17.2% and low bicarbonate level in 13.6% of HIV-tested patients. Plasma magnesium was out of the normal range in 38.9% and blood glucose in 25.3% of the tested patients. When CD4 count was below 200/mm3, 9.2% of tested patients experienced low serum calcium (vs. 0.5% if CD4 count >200/mm3, p < 0.002), 11.4% increased creatinine plasma level (vs. 2.3% if CD4 count >200/mm3, p < 0.0001) and 24.5% low serum bicarbonate (vs. 13.7% if CD4 count >200/mm3, p < 0.0001). Protease inhibitor treatment was a significant risk factor of hyperuricemia (p < 0.003). Non-nucleoside reverse transcriptase inhibitor therapy was significantly associated with less hyperuricemia (OR = 0.6, 95% CI 0.38–0.96) and with hypophosphatemia (OR = 2.0, 95% CI 1.1–3.4). Conclusions: The profile of biochemical abnormalities in HIV-infected patients has changed, hyperuricemia and hypophosphatemia being the most prevalent. Causes are poorly understood. Interpretation of drug-induced side effects in the HIV patient is only meaningful if performed versus a control group of patients.Keywords
This publication has 21 references indexed in Scilit:
- Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathyAIDS, 2004
- Is There a Pathogenetic Role for Uric Acid in Hypertension and Cardiovascular and Renal Disease?Hypertension, 2003
- Severe Deficiency of 1,25-Dihydroxyvitamin D3 in Human Immunodeficiency Virus Infection: Association with Immunological Hyperactivity and Only Minor Changes in Calcium HomeostasisJournal of Clinical Endocrinology & Metabolism, 1998
- Hyponatremia in hospitalized patients with the acquired immunodeficiency syndrome (AIDS) and the AIDS-Related complexThe American Journal of Medicine, 1993
- Metabolism of 2′,3′-dideoxyinosine (ddI) in human blood.Published by Wiley ,1992
- Frequency of hyponatremia and nonosmolar vasopressin release in the acquired immunodeficiency syndromeJAMA, 1990
- Hyponatremia in Patients with the Acquired Immunodeficiency SyndromeNephron, 1989
- Severe hypophosphatemia in hospitalized patientsArchives of internal medicine (1960), 1988
- Associated Focal and Segmental Glomerulosclerosis in the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1984
- Effect of Oestrogen Therapy on Plasma and Urinary Levels of Uric AcidBMJ, 1973